Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (11): 1183-1182.doi: 10.3969/j.issn.1000-6621.2020.11.008
• Original Articles • Previous Articles Next Articles
YING Ruo-yan, HUANG Xiao-chen, WANG Jie, LIU Yi-dian, SHA Wei, YANG Hua()
Received:
2020-07-31
Online:
2020-11-10
Published:
2020-11-13
Contact:
YANG Hua
E-mail:yanghua97065@163.com
YING Ruo-yan, HUANG Xiao-chen, WANG Jie, LIU Yi-dian, SHA Wei, YANG Hua. Clinical analysis of drug sensitivity tests of various drug-resistant MTB isolates against different combinations of anti-tuberculosis drugs in vitro[J]. Chinese Journal of Antituberculosis, 2020, 42(11): 1183-1182. doi: 10.3969/j.issn.1000-6621.2020.11.008
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.11.008
板孔编号 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
A | - | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 |
B | 0.125 | 0.03+0.125 | 0.06+0.125 | 0.125+0.125 | 0.25+0.125 | 0.5+0.125 | 1+0.125 | 2+0.125 | 4+0.125 | 8+0.125 | 16+0.125 | 32+0.125 |
C | 0.25 | 0.03+0.25 | 0.06+0.25 | 0.125+0.25 | 0.25+0.25 | 0.5+0.25 | 1+0.25 | 2+0.25 | 4+0.25 | 8+0.25 | 16+0.25 | 32+0.25 |
D | 0.5 | 0.03+0.5 | 0.06+0.5 | 0.125+0.5 | 0.25+0.5 | 0.5+0.5 | 1+0.5 | 2+0.5 | 4+0.5 | 8+0.5 | 16+0.5 | 32+0.5 |
E | 1 | 0.03+1 | 0.06+1 | 0.125+1 | 0.25+1 | 0.5+1 | 1+1 | 2+1 | 4+1 | 8+1 | 16+1 | 32+1 |
F | 2 | 0.03+2 | 0.06+2 | 0.125+2 | 0.25+2 | 0.5+2 | 1+2 | 2+2 | 4+2 | 8+2 | 16+2 | 32+2 |
G | 4 | 0.03+4 | 0.06+4 | 0.125+4 | 0.25+4 | 0.5+4 | 1+4 | 2+4 | 4+4 | 8+4 | 16+4 | 32+4 |
H | 8 | 0.03+8 | 0.06+8 | 0.125+8 | 0.25+8 | 0.5+8 | 1+8 | 2+8 | 4+8 | 8+8 | 16+8 | - |
药品 | MIC值 [M(Q1,Q3)mg/L] | Z值 | P值 | 药品 | MIC值 [M(Q1,Q3)mg/L] | Z值 | P值 |
---|---|---|---|---|---|---|---|
-4.855 | <0.001 | -6.908 | <0.001 | ||||
H(单药H) | 4(1,8) | R(单药R) | 24(2,64) | ||||
与R组合后H | 2(1,4) | 与H组合后R | 1(0.25,16) | ||||
-8.386 | <0.001 | -8.632 | <0.001 | ||||
Rfb(单药Rfb) | 0.5(0.125,1) | Rft(单药Rft) | 4(4,4) | ||||
与Mfx-Pa组合后Rfb | 0.125(0.03125,0.125) | 与Mfx-Pa组合后Rft | 1(1,1) | ||||
Mfx(单药Mfx) | 0.5(0.06,1) | Pa(单药Pa) | 8(4,8) | ||||
与Pa组合后Mfx | 0.5(0.06,1) | -2.494 | 0.013 | 与Mfx组合后Pa | 0.0075(0.0075,0.875) | -8.094 | <0.001 |
与Pa-Rfb组合后Mfx | 0.25(0.06,1) | -1.521 | 0.128 | 与Mfx-Rfb组合后Pa | 0.0075(0.0075,0.125) | -8.335 | <0.001 |
与Pa-Rft组合后Mfx | 0.25(0.03,1) | -0.363 | 0.717 | 与Mfx-Rft组合后Pa | 0.0225(0.0075,0.5) | -7.771 | <0.001 |
不同耐药菌株 | H-R | Mfx-Pa | Mfx-Pa-Rfb | Mfx-Pa-Rft |
---|---|---|---|---|
MDR-MTB(36株) | ||||
协同作用 | 4(11.1) | 2(5.6) | 7(19.4) | 11(30.6) |
无相关 | 32(88.9) | 34(94.4) | 27(75.0) | 21(58.3) |
拮抗 | 0(0.0) | 0(0.0) | 2(5.6) | 4(11.1) |
XDR-MTB(54株) | ||||
协同作用 | 6(11.1) | 3(5.6) | 9(16.7) | 10(18.5) |
无相关 | 48(88.9) | 51(94.4) | 37(68.5) | 36(66.7) |
拮抗 | 0(0.0) | 0(0.0) | 8(14.8) | 8(14.8) |
单耐H(2株) | ||||
协同作用 | 1(1/2) | 0(0/2) | 0(0/2) | 1(1/2) |
无相关 | 1(1/2) | 2(2/2) | 2(2/2) | 1(1/2) |
拮抗 | 0 | 0 | 0 | 0 |
[1] | 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508. |
[2] |
Ragonnet R, Trauer JM, Denholm JT, et al. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infect Dis, 2017,17(1):36. doi: 10.1186/s12879-016-2171-1.
URL pmid: 28061832 |
[3] | 沙巍, 肖和平. 未来理想的抗结核药物与化学治疗方案. 中国防痨杂志, 2012,34(11):693-696. |
[4] | 张琳琳, 杨华, 肖和平, 等. 棋盘法检测复治新方案核心药物对耐多药和广泛耐药结核分枝杆菌体外的联合作用. 中华结核和呼吸杂志, 2016,39(6):464-468. doi: 10.3760/cma.j.issn.1001-0939.2016.06.013. |
[5] |
Rey-Jurado E Tudó G de la Bellacasa JP, et al. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents, 2013,41(3):278-280. doi: 10.1016/j.ijantimicag.2012.11.011.
URL pmid: 23312604 |
[6] | Moody JA. Synergism Testing: Broth Microdilution Checkerboard and Broth Macrodilution Methods, In: Clinical Microbiology Procedures Handbook. Washington DC:American Society Microbiology, 1992: 22. |
[7] |
Daley CL, Caminero JA. Management of Multidrug-Resistant Tuberculosis. Semin Respir Crit Care Med, 2018,39(3):310-324. doi: 10.1055/s-0038-1661383.
doi: 10.1055/s-0038-1661383 URL pmid: 30071546 |
[8] |
López-Gavín A, Tudó G, Vergara A, et al. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid. Int J Antimicrob Agents, 2015,46(5):582-585. doi: 10.1016/j.ijantimicag.2015.08.004.
doi: 10.1016/j.ijantimicag.2015.08.004 URL pmid: 26421981 |
[9] |
Li G, Zhang J, Jiang Y, et al. Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolates in China. J Glob Antimicrob Resist, 2019,20:275-281. doi: 10.1016/j.jgar.2019.08.005.
doi: 10.1016/j.jgar.2019.08.005 URL pmid: 31425771 |
[10] |
Rothstein DM. Rifamycins, Alone and in Combination. Cold Spring Harb Perspect Med, 2016,6(7):a027011. doi: 10.1101/cshperspect.a027011.
doi: 10.1101/cshperspect.a027011 URL pmid: 27270559 |
[11] |
Lee H, Ahn S, Hwang NY, et al. Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis. Int J Infect Dis, 2017,65:135-141. doi: 10.1016/j.ijid.2017.10.013.
doi: 10.1016/j.ijid.2017.10.013 URL pmid: 29224631 |
[12] |
Yan L, Kan X, Zhu L, et al. Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China. Clin Ther, 2018,40(3):440-449. doi: 10.1016/j.clinthera.2018.01.013.
doi: 10.1016/j.clinthera.2018.01.013 URL pmid: 29519716 |
[13] | 刘宇红, 高微微, 李亮, 等. 单耐药和多耐药复治菌阳肺结核个体化治疗效果探讨. 中华结核和呼吸杂志, 2018,41(1):25-31. doi: 10.3760/cma.j.issn.1001-0939.2018.01.008. |
[1] | Wang Xueyu, Wang Yujin, Chu Naihui, Kang Wanli, Nie Wenjuan. A preliminary study on the enhanced in vivo exposure of sudapyridine in Mycobacterium abscessus-infected rats with the co-administration of clofazimine or clarithromycin [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 150-157. |
[2] | Zhang Chao, Yu Xia, Huang Hairong, Liu Wei, Liu Tao. Evaluation of the in vitro antimicrobial effects of sevoflurane on Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 158-163. |
[3] | Chen Shuangshuang, Tian Lili, Wang Nenhan, Yang Xinyu, Zhao Yanfeng, Li Chuanyou, Dai Xiaowei. Analysis of in vitro antibacterial effects of 17 antibiotics against rapidly growing mycobacteria in the Beijing area [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1056-1062. |
[4] | Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei. Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950. |
[5] | Xue Lian, Ju Meng, Huang Yi, Zhao Guolian, Zhang Yuhao, Wang Sihan, Lei Ying, Dang Liyun, Zuo Lei. A preliminary study of the in vitro bactericidal effect of low-temperature plasma technology on the Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 557-561. |
[6] | Song Hongge, Liu Weigao, Chen Li. A comparative study on the therapeutic effects of total hip joint type spacer and pressure model spacer in patients with mid to late stage hip tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 562-566. |
[7] | Cheng Mengli, Jiang Guanglu, Huo Fengmin, Xue Yi, Yu Xia. Evaluation of in vitro activity of fusidic acid against mycobacteria [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 461-466. |
[8] | Pei Shaojun, Ou Xichao. Interpretation of the World Health Organization’s Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance (2nd Edition) [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 260-266. |
[9] | Li Ting, Liu Shuang, Wang Danxia, Lu Jia, Cheng Qianqian, Chen Chuang, He Jin’ge, Zhang Linglin, Xia Yong, Li Jing, Zhang Shu, Gao Wenfeng, Xia Lan. Evaluation of health economics of implementation of tuberculosis prevention and control program in Sichuan Province from 2011 to 2020 [J]. Chinese Journal of Antituberculosis, 2024, 46(3): 333-339. |
[10] | Gulina Badeerhan, Liu Nianqiang, Yipaer Aihaiti, Wang Le, Wang Senlu, Zulikatiayi Abudula, Wang Mingzhe, Zhang Jing, Wang Xinqi, Bi Hongbo. The effect of GeneXpert MTB/RIF detection technology in tuberculosis prevention and control program in Xinjiang [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 173-177. |
[11] | Ma Shiran, Chen Suting, Huang Hairong, Duan Hongfei. In vitro inhibitory and intracellular bactericidal activity of omadacycline against Mycobacterium abscessus [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1442-1447. |
[12] | Liu Shuren, Fu Lin, Wang Lianbo, Zhao Guisong, Li Zhuo, Dong Zhaoliang. Application of blood management in the perioperative period of lumbar tuberculosis under the concept of enhanced recovery after surgery [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1343-1349. |
[13] | Li Jing, Jiang Qi, Jiang Yuan, Shen Xin. Evaluation of performance of PCR fluorescent probe method for detecting Mycobacterium tuberculosis complex and rifampicin resistance [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1250-1258. |
[14] | Song Yuanyuan, Xia Hui, Zhao Yanlin. Development process of setting of critical concentrations for phenotypic drug susceptibility testing of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(7): 631-638. |
[15] | Song Ruixue, Wei Rongrong, Dong Jing, Jia Hongyan, Du Boping, Sun Qi, Xing Aiying, Li Zihui, Zhu Chuanzhi, Zhang Zongde, Pan Liping. The performance of interferon gamma-induced protein 10 mRNA detection technology in auxiliary diagnosis of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 471-476. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||